Corvus Pharmaceuticals, Inc. (CRVS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Corvus Pharmaceuticals, Inc. (CRVS) closed at USD 9.38 on 2026-10-14, a change of +23.6 % over the past year, with a market capitalization of USD 828.59M.

Corvus Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Corvus Pharmaceuticals, Inc. key figures

Previous close

USD 9.38 (2026-10-14)

1-year change

+23.6 %

Market cap

USD 828.59M

Enterprise value

USD 614.09M

P/E ratio (trailing)

-15.15

P/E ratio (forward)

-9.23

EPS (trailing)

-0.65

EPS (forward)

-1.07

PEG ratio

n/a

Price to book

3.68

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

15.44

Employees

37

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Corvus Pharmaceuticals, Inc. and compare it with other stocks.